Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2-BC).

被引：4
|
作者：
Munster, Pamela N.
Hamilton, Erika Paige
Franklin, Catherine
Bhansali, Suraj
Wan, Kitty
Hewes, Becker
Juric, Dejan
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] Novartis Inst Biomed Res, Cambridge, MA USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Pharma AG, Basel, Switzerland
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, Her2-breast cancer.
    Munster, Pamela N.
    Hamilton, Erika Paige
    Estevez, Laura G.
    De Boer, Richard H.
    Mayer, Ingrid A.
    Campone, Mario
    Asano, Shizuka
    Bhansali, Suraj
    Zhang, Vickie
    Hewes, Becker
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [2] Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2-breast cancer: Safety, preliminary efficacy and molecular analysis
    Juric, Dejan
    Hamilton, Erika
    Garcia Estevez, Laura
    De Boer, Richard H.
    Mayer, Ingrid
    Campone, Mario
    Asano, Shizuka
    Bhansali, Suraj
    Zhang, Vickie
    Hewes, Becker
    Munster, Pamela
    CANCER RESEARCH, 2015, 75
  • [3] Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.
    Juric, Dejan
    Munster, Pamela N.
    Campone, Mario
    Ismail-Khan, Roohi
    Garcia-Estevez, Laura
    Hamilton, Erika Paige
    Becerra, Carlos
    De Boer, Richard H.
    Hui, Rina
    Goncalves, Anthony
    Wang, Yingbo
    Dhuria, Shyeilla V.
    Kalimi, Ghulam H.
    Lorenc, Karen Cristina Rodriguez
    Mayer, Ingrid A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2-BC).
    Dawson, Sarah-Jane
    Wein, Lironne
    Silva, Maria Joao
    Luen, Stephen James
    VanGeelen, Courtney
    Moodie, Kate
    Savas, Peter
    Weng, Chen-Fang
    Bujak, Andjelija Zivanovic
    Yeung, Miriam M.
    Ftouni, Sarah
    Kuykhoven, Keilly
    Hicks, Rodney J.
    Francis, Prudence A.
    Lee, Chee Khoon
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2-BC)
    Majid, Oneeb
    Xiao, Jianjun Alan
    Sahmoud, Tarek
    Yasuda, Sanae
    Cantagallo, Lisa
    Hamilton, Erika P.
    Pluard, Timothy
    Juric, Dejan
    Gualberto, Antonio
    Husseiin, Ziad
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2
    Sonke, G. S.
    Hart, L. L.
    Campone, M.
    Erdkamp, F.
    Janni, W.
    Verma, S.
    Villanueva, C.
    Jakobsen, E.
    Alba, E.
    Wist, E.
    Favret, A. M.
    Bachelot, T.
    Hegg, R.
    Wheatley-Price, P.
    Souami, F.
    Sutradhar, S.
    Miller, M.
    Germa, C.
    Burris, H. A.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S1 - S2
  • [7] A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer
    Mayer, Ingrid A.
    Abramson, Vandana G.
    Formisano, Luigi
    Balko, Justin M.
    Estrada, Monica V.
    Sanders, Melinda E.
    Juric, Dejan
    Solit, David
    Berger, Michael F.
    Won, Helen H.
    Li, Yisheng
    Cantley, Lewis C.
    Winer, Eric
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2017, 23 (01) : 26 - 34
  • [8] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
  • [9] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
  • [10] Clinical considerations for estrogen receptor-negative/ progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer
    Rala de Paula, Bruno Henrique
    Crocamo, Susanne
    Bines, Jose
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
12345